Jaffetilchin Investment Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-4,662
Closed -$517K 463
2025
Q3
$517K Buy
+4,662
New +$530K 0.03% 278
2024
Q4
Sell
-744
Closed -$62.3K 725
2024
Q3
$62.3K Buy
+744
New +$56.8K ﹤0.01% 544
2023
Q3
Sell
-4,917
Closed -$379K 352
2023
Q2
$379K Buy
+4,917
New +$392K 0.04% 240
2021
Q4
Sell
-4,104
Closed -$287K 362
2021
Q3
$287K Buy
+4,104
New +$288K 0.03% 280
2016
Q1
Sell
-4,285
Closed -$434K 205
2015
Q4
$434K Buy
4,285
+1,400
+49% +$146K 0.14% 105
2015
Q3
$283K Sell
2,885
-8,055
-74% -$895K 0.11% 150
2015
Q2
$1.28M Buy
10,940
+5,429
+99% +$593K 0.38% 40
2015
Q1
$541K Buy
+5,511
New +$560K 0.16% 99
2014
Q4
Sell
-10,456
Closed -$1.11M 213
2014
Q3
$1.11M Buy
+10,456
New +$1.02M 0.41% 34
2014
Q2
Sell
-4,636
Closed -$329K 216
2014
Q1
$329K Sell
4,636
-37
-0.8% -$2.9K 0.13% 139
2013
Q4
$351K Sell
4,673
-237
-5% -$16.5K 0.17% 106
2013
Q3
$309K Sell
4,910
-851
-15% -$50.9K 0.18% 107
2013
Q2
$295K Buy
+5,761
New +$300K 0.2% 120

Other funds holding GILD

Jaffetilchin Investment Partners's GILD Position: Q4 2025 in Review

Jaffetilchin Investment Partners sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 4,662 shares — an estimated $517K sold.

Jaffetilchin Investment Partners first reported a position in GILD in Q2 2013 and held it in 13 quarters. The position peaked at $1.28M in Q2 2015. 2,220 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

  • Jaffetilchin Investment Partners reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 4,662 Gilead Sciences shares in Q4 2025, an estimated $517K.
  • Jaffetilchin Investment Partners first reported a position in Gilead Sciences in Q2 2013 and held it in 13 quarters.
  • Jaffetilchin Investment Partners's Gilead Sciences position peaked at $1.28M in Q2 2015.
  • 2,220 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2025, filed 15 Jan 2026.